Clinical Trial Detail

NCT ID NCT03397173
Title TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Case Comprehensive Cancer Center
Indications

central nervous system leukemia

myelodysplastic syndrome

myelodysplastic/myeloproliferative neoplasm

acute myeloid leukemia

Therapies

Azacitidine + Vitamin C

Age Groups: adult senior

Additional content available in CKB BOOST